Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

69116 1519310944HCLSReviewSerbiaFebruary2018.pdf
Energy Boardroom

U.K.'s NICE throws Astellas a bone on Xtandi–or does it?

09.05.2014 / Fierce Pharma

First it was good news, then it was bad news, and now it's good news again for Astellas' prostate cancer treatment Xtandi (enzalutamide) and its recommendation from the U.K.'s National Institute for Health and Care Excellence. At least it appears that way.

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: